title: Ureaplasma urealyticum destructive septic arthritis in a patient with systemic lupus erythematosus after rituximab therapy.
authors.forename: Tiphaine Miquel
authors.initials: TM
authors.lastname: Goulenok
authors.forename: Suzanne
authors.initials: S
authors.lastname: Bialek
authors.forename: Sandrine
authors.initials: S
authors.lastname: Gaudart
authors.forename: Cécile
authors.initials: C
authors.lastname: Bébéar
authors.forename: Bruno
authors.initials: B
authors.lastname: Fantin
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects*; D001170:Arthritis, Infectious / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology*; D004318:Doxycycline / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D007155:Immunologic Factors / Q000009:adverse effects*; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy; D008279:Magnetic Resonance Imaging; D008297:Male; D000069283:Rituximab; D016896:Treatment Outcome; D016869:Ureaplasma Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D016990:Ureaplasma urealyticum / Q000302:isolation & purification / Q000502:physiology; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab; D004318:Doxycycline